Skip to main content

Table 1 Demographic and clinical characteristics of study participants

From: The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity

 

CU (N = 124)

MCI (N = 58)

AD (N = 34)

Non-AD (N = 26)

Age, median (Q1-Q3)

70.3 (65.7–74.7)

72.2 (66.3–75.9)

66.9 (61.1–73.5)

64.0 (57.5–69.6)

Female, n (%)

89 (71.8%)

35 (60.3%)

21 (61.8%)

15 (57.7%)

YOE, median (Q1-Q3)

15.0 (12.8–18.0)

16.0 (12.0–17.8)

15.0 (13.3–16.0)

15.0 (12.0–17.0)

MMSE, Median (Q1-Q3)

29.0 (28.0–30.0) [11]

29.0 (27.0–29.0)

[8]

23.0 (20.0–25.8) [4]

26.0 (23.8–29.0) [6]

APOE ε4 carriers, No. (%)

29 (23.4%) [0]

26 (44.8%) [2]

20 (58.8%) [0]

3 (11.5%) [1]

Amyloid status, No. (%)

30 (24.2%) [0]

37 (63.8%) [0]

33 (97.1%) [0]

0 (0%) [0]

eGFR Median (Q1-Q3)

92.8 (84.2–97.3)

93.1 (83.1–97.2) 

92.3 (87.8–97.5)

100 (88.6–104)

Plasma p-tau217, median (Q1-Q3), pg/mL

0.274 (0.170–0.405) [13]

0.677 (0.428–0.940) [7]

1.31 (0.671–1.83) [3]

0.273 (0.190–0.353) [0]

Plasma p-tau181, median (Q1-Q3), pg/mL

7.12 (5.46–10.7) [1]

8.71 (6.82–11.8) [1]

13.6 (9.21–16.9)

[0]

7.49 (4.74–10.6)

[0]

Plasma p-tau231, median (Q1-Q3), pg/mL

13.0 (10.0–16.7) [0]

18.5 (13.8–23.7) [2]

22.8 (15.9–28.6) [1]

13.4 (11.1–19.8) [0]

Plasma NTA-tau, median (Q1-Q3), pg/mL

0.177 (0.111–0.308) [5]

0.242 (0.112–0.432) [1]

0.522 (0.384–0.635) [1]

0.195 (0.148–0.473) [0]

Plasma GFAP, median (Q1-Q3), pg/mL

154 (109–195) [1]

186 (134–232) [0]

270 (190–312) [0]

140 (72.7–189) [0]

Plasma NfL, median (Q1-Q3), pg/mL

19.4 (14.5–26.9) [1]

23.6 (16.7–30.1) [0]

31.2 (22.0–36.2) [0]

23.3 (14.4–38.4) [0]

Plasma Aβ42, median (Q1-Q3), pg/mL

6.65 (5.68–7.83) [1]

6.56 (5.52–7.19) [0]

5.46 (4.32–6.38) [0]

6.84 (5.23–8.33) [0]

Plasma Aβ40, median (Q1-Q3), pg/mL

92.0 (80.5–101) [1]

91.6 (85.7–106) [0]

97.0 (78.9–103) [0]

86.7 (75.5–103) [0]

Plasma Aβ42/40, median (Q1-Q3), pg/mL

0.0725 (0.0630–0.0828) [1]

0.0664 (0.0616–0.0778) [0]

0.0601 (0.0551–0.0658) [0]

0.0767 (0.0685–0.0854) [0]

  1. Categorical variables are reported as counts and percentages, while continuous variables are presented as median values with interquartile ranges (Q1-Q3). Missing values are reported in brackets next to the respective variables
  2. Abbreviations CU Cognitively Unimpaired, MCI Mild Cognitive Impairment, AD Alzheimer's Disease, Non-AD Non-Alzheimer's Disease, YOE Years of Education, MMSE Mini-Mental State Examination, APOE Apolipoprotein E, eGFR Estimated Glomerular Filtration Rate, p-tau phosphorylated tau, NTA-tau N-terminal containing tau fragments, GFAP Glial Fibrillary Acidic Protein, NfL Neurofilament Light chain, Aβ Amyloid Beta
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193